Acadian Asset Management LLC Has $1.55 Million Stock Position in Theravance Biopharma, Inc. $TBPH

Key Points

• Acadian Asset Management LLC significantly increased its stake in Theravance Biopharma, acquiring an additional 174,451 shares during the first quarter, bringing its total holdings to approximately 0.35% of the company, valued at $1,554,000.
• Brokerages have issued a series of upgrades for Theravance Biopharma, with an average rating of "Strong Buy" and a price target around $23.00, reflecting positive market sentiment toward the company's growth potential.
• Theravance Biopharma's stock recently opened at $13.87 but has seen fluctuations, with a 12-month price range between $7.88 and $14.55, indicating variable investor interest.

Acadian Asset Management LLC increased its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 121,993.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 174,594 shares of the biopharmaceutical company's stock after purchasing an additional 174,451 shares during the quarter. Acadian Asset Management LLC owned approximately 0.35% of Theravance Biopharma worth $1,554,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Theravance Biopharma by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock valued at $18,579,000 after acquiring an additional 69,919 shares during the period. Park West Asset Management LLC boosted its holdings in Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after buying an additional 11,256 shares in the last quarter. Nuveen Asset Management LLC increased its position in Theravance Biopharma by 10.9% during the fourth quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company's stock worth $4,665,000 after purchasing an additional 48,635 shares during the last quarter. Bank of America Corp DE grew its holdings in Theravance Biopharma by 2.7% during the 4th quarter. Bank of America Corp DE now owns 481,475 shares of the biopharmaceutical company's stock valued at $4,531,000 after purchasing an additional 12,596 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Theravance Biopharma by 1.6% in the 4th quarter. Northern Trust Corp now owns 389,980 shares of the biopharmaceutical company's stock valued at $3,670,000 after purchasing an additional 6,198 shares during the last quarter. 99.10% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president owned 326,918 shares in the company, valued at $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Price Performance

NASDAQ:TBPH traded down $0.59 during trading hours on Friday, reaching $13.88. The company's stock had a trading volume of 465,356 shares, compared to its average volume of 508,645. The company has a market cap of $699.00 million, a price-to-earnings ratio of 57.83 and a beta of 0.05. The business's 50-day moving average is $12.67 and its 200-day moving average is $10.76. Theravance Biopharma, Inc. has a one year low of $7.88 and a one year high of $14.55.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on TBPH shares. B. Riley assumed coverage on shares of Theravance Biopharma in a research note on Friday, September 12th. They issued a "buy" rating and a $28.00 price objective for the company. Zacks Research downgraded shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 15th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 16th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a research note on Tuesday, June 17th. Finally, BTIG Research boosted their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Theravance Biopharma currently has a consensus rating of "Buy" and an average price target of $23.00.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.